List view / Grid view
Researchers have applied a computational analysis based on networks in order to identify biologically relevant phenotypes apart from those currently defined by the WHO...
Venoms are continually being researched as potential chemicals for medicinal therapeutics to treat autoimmune diseases and diabetes...
CMPK2 inhibitors may reduce inflammation, pain and tissue damage in arthritis and gout and in Alzheimer’s may slow loss of cognitive function...
Blindness in children has been linked to a recessive genetic disorder caused by the MARK3 gene...
The outer membrane surrounding the cell wall of bacteria may be a key target for approaches to a new form of antibacterial drugs...
Breath tests analysing organic compounds in exhaled breath could be used as a new diagnostic tool for pancreatic cancer...
A new system, pGENMi, could predict genomic features associated with drug responses, by identifying differences in gene expression...
Vascular Endothelial Growth Factor C (VEGF-C) could aid the repair and recovery of hearts after a heart attack, by enabling immune cells to clear dead and dying cells...
The Nobel Prize-winning observations and discoveries of John B. Gurdon and Shinya Yamanaka have ignited an explosion of excitement around the potential use of stem cells in research and treatment of human disease.
Scientists in the Netherlands have investigated the structure of the human glutamine transporter ASCT2 in a bid to generate leads for cancer drug development.
A team of researchers in Spain show for the first time the complete epigenome of chronic lymphocytic leukaemia, the most common type of leukaemia.
A new study by the University of Arizona (UA) suggests that revealing all the steps required to activate an enzyme called a protein kinase may help identify new ways to target cancer.
There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.
Researchers in the US have undertaken meta-analysis studies to ascertain the optimum approach for doctors treating rare mixed phenotype acute leukaemia (MPAL). They found that a less-toxic regimen gives better results.
